Edgewise Therapeutics Inc (EWTX)
32.20
+0.22
(+0.69%)
USD |
NASDAQ |
Nov 22, 16:00
33.00
+0.80
(+2.48%)
After-Hours: 20:00
Edgewise Therapeutics Cash from Financing (Quarterly): 3.333M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.333M |
| June 30, 2024 | 1.952M |
| March 31, 2024 | 241.07M |
| December 31, 2023 | 52.99M |
| September 30, 2023 | -0.211M |
| June 30, 2023 | 0.369M |
| March 31, 2023 | 0.021M |
| December 31, 2022 | -0.303M |
| September 30, 2022 | 129.69M |
| June 30, 2022 | 0.179M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.073M |
| December 31, 2021 | 0.293M |
| September 30, 2021 | 0.037M |
| June 30, 2021 | -0.896M |
| March 31, 2021 | 186.95M |
| December 31, 2020 | 95.00M |
| September 30, 2020 | 25.14M |
| June 30, 2020 | 0.135M |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.896M
Minimum
Jun 2021
241.07M
Maximum
Mar 2024
38.73M
Average
0.293M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | -5.974M |
| Cytokinetics Inc | 3.425M |
| Vanda Pharmaceuticals Inc | -- |
| Vertex Pharmaceuticals Inc | -387.50M |
| Sarepta Therapeutics Inc | 13.76M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.37M |
| Cash from Investing (Quarterly) | 25.36M |
| Free Cash Flow | -110.10M |
| Free Cash Flow Per Share (Quarterly) | -0.2973 |
| Free Cash Flow Yield | -4.03% |